Arcus Biosciences, Inc. (RCUS) compared with its closest peers (AKBA, ANAB, LFVN, PBYI, LGND). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Akebia Therapeutics, AnaptysBio, LifeVantage, Puma Biotechnology, Ligand Pharmaceuticals, Harrow Health, IDEAYA Biosciences, Vanda Pharmaceuticals, Xeris Biopharma and Rigel Pharmaceuticals share Arcus Biosciences's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $243.63M | -80.3 |
| AnaptysBio, Inc. (ANAB) | $1.68B | -105.4 |
| LifeVantage Corporation (LFVN) | $84.02M | 11.6 |
| Puma Biotechnology, Inc. (PBYI) | $476.97M | 17.9 |
| Ligand Pharmaceuticals Incorporated (LGND) | $5.70B | 41.0 |
| Harrow Health, Inc. (HROW) | $1.53B | -350.0 |
| IDEAYA Biosciences, Inc. (IDYA) | $3.83B | -27.0 |
| Vanda Pharmaceuticals Inc. (VNDA) | $318.12M | -2.4 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
RCUS overview · RCUS earnings · RCUS financials · RCUS KPIs · RCUS documents · RCUS ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.